BEAT - HeartBeam forms strategic alliance with Samsung for cardiac diagnostics; shares surge 35%

2023-05-30 09:03:45 ET

• HeartBeam ( NASDAQ: BEAT ) is trading 35% higher premarket after it had entered into a strategic alliance with Samsung to revolutionize cardiac diagnostics.
• The partnership combines HeartBeam's expertise in cardiac assessment and monitoring with Samsung's technologies.
• The companies would integrate HeartBeam's telehealth platform and Samsung's FDA-cleared arrhythmia detection tool for cardiac diagnostics for patients at home.
• HeartBeam's recent acquisition of LIVMOR's assets strengthens its position in the cardiac technology sector.
• The collaboration focuses on improving healthcare for veterans and addressing major cardiac conditions.
• LIVMOR's Halo Atrial Fibrillation ( AF ) Detection System plays a significant role in the partnership.
• The collaboration has resulted in an FDA-cleared solution for Atrial Fibrillation detection using Samsung's Galaxy watch and tablet.
• The initiative aims to improve heart attack detection and enhance patient care outside of traditional medical settings.
• Press Release

For further details see: